Breast cancer in young women; Triple-negative breast cancer; Neoadjuvant therapy for breast cancer; Novel therapies for breast cancer
Dr. Prowell received her B.A. degree in Languages & Literature with honors from Bard College. She received her M.D. degree from Johns Hopkins University School of Medicine inBaltimore, Maryland, where she was elected to the Phi Beta Kappa and Alpha Omega Alpha honor societies. She subsequently completed an internal medicine residency in the Osler Housestaff Training Program at Johns Hopkins Hospital and a medical oncology fellowship within the Breast Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. During fellowship, she wrote and conducted three investigator-initiated translational breast cancer trials. She was awarded a Young Investigator Award from the American Society of Clinical Oncology (ASCO) and twice awarded the Pearl M. Stetler Research Fund for Women for her breast cancer research.
In 2006, Dr. Prowell accepted a joint appointment as faculty at the Johns Hopkins School of Medicine in the Breast Cancer Program and as a Medical Officer at the FDA. She currently serves as the Scientific Lead for Breast Cancer in the Office of Hematology & Oncology Products at the FDA and is an Assistant Professor of Oncology in the Johns Hopkins Breast Cancer Program. She has been an invited speaker at numerous academic institutions, national medical conferences, and patient advocacy gatherings and is a two-time recipient of FDA''s Excellence in Communication Award. Recently she has helped to pioneer a pathway to accelerated approval for drugs used to treat patients with high-risk, early-stage breast cancers, such as triple-negative breast cancer, in the neoadjuvant setting.
Dr. Prowell remains committed to the clinical care of women and men with breast cancer and practices at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, where she staffs the second opinion breast cancer clinic. Her particular areas of clinical and research interest include: triple-negative breast cancer, development of novel agents for breast cancer treatment, neoadjuvant therapy for breast cancer, and the unique challenges of breast cancer in younger women.
When asked what motivated her to pursue the joint appointment she currently holds at Johns Hopkins and the FDA, she said, "The two positions really complement one another. In my clinical practice, I have the privilege of spending as much time as it takes to help my patients make the most informed choices possible about their treatment. I see the challenges that my patients face up close, and I feel the urgency to get novel therapies to them. At the FDA, I have the opportunity to shape at a very high level drug development programs to ensure that the most promising treatments will reach patients as rapidly as possible. I love what I do. I feel thankful every day to wear both of these hats as an oncologist to make things better for patients living with this disease. I couldn''t imagine doing anything different." She pauses before adding, "though I would be very happy to be put out of business. I guess if we do our jobs well enough, that''s precisely what will happen! I hope I live to see that day."